Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,587
  • Shares Outstanding, K 21,187
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,480 K
  • 60-Month Beta -0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33
Trade APRE with:

Options Overview

Details
  • Implied Volatility 130.36%
  • Historical Volatility 71.83%
  • IV Percentile 25%
  • IV Rank 10.20%
  • IV High 344.76% on 04/05/21
  • IV Low 106.01% on 06/25/21
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,069
  • Volume Avg (30-Day) 2,189
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 13,451
  • Open Int (30-Day) 15,462

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.48
  • Number of Estimates 3
  • High Estimate -0.45
  • Low Estimate -0.51
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +4.05%
on 07/23/21
5.89 -25.81%
on 07/21/21
-0.46 (-9.52%)
since 06/23/21
3-Month
3.88 +12.63%
on 05/13/21
7.80 -43.97%
on 06/16/21
-0.24 (-5.21%)
since 04/23/21
52-Week
3.88 +12.63%
on 05/13/21
31.45 -86.10%
on 09/18/20
-21.30 (-82.98%)
since 07/23/20

Most Recent Stories

More News
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced...

APRE : 4.37 (+0.46%)
Implied Volatility Surging for Aprea (APRE) Stock Options

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

APRE : 4.37 (+0.46%)
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

RHHBY : 47.0300 (+1.31%)
ABBV : 118.19 (+0.55%)
APRE : 4.37 (+0.46%)
BNTX : 281.96 (+0.35%)
Thinking about buying stock in Aprea Therapeutics, RA Medical Systems, AMC Entertainment, Torchlight Energy Resources, or Appharvest?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, RMED, AMC, TRCH, and APPH.

AC : 37.36 (+0.03%)
MDSY : 0.73 (+4.29%)
RMED : 3.37 (-7.92%)
APPH : 12.16 (-4.48%)
APRE : 4.37 (+0.46%)
TRCH : 4.95 (+4.21%)
AMC : 36.99 (-0.67%)
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

-- 37% CR rate in 30 efficacy-evaluable patients

APRE : 4.37 (+0.46%)
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced...

APRE : 4.37 (+0.46%)
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced...

APRE : 4.37 (+0.46%)
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today...

APRE : 4.37 (+0.46%)
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today...

APRE : 4.37 (+0.46%)
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today...

APRE : 4.37 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 4.70
2nd Resistance Point 4.57
1st Resistance Point 4.47
Last Price 4.37
1st Support Level 4.23
2nd Support Level 4.10
3rd Support Level 4.00

See More

52-Week High 31.45
Fibonacci 61.8% 20.92
Fibonacci 50% 17.67
Fibonacci 38.2% 14.41
Last Price 4.37
52-Week Low 3.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar